NCT06578533 (KEEP-ON) is a Phase 3 clinical trial of Sodium Zirconium Cyclosilicate in Chronic Kidney Diseases, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

Who is sponsoring NCT06578533?

NCT06578533 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

What drugs are being tested in NCT06578533?

Interventions in NCT06578533: Sodium Zirconium Cyclosilicate.

What condition does NCT06578533 study?

NCT06578533 studies Chronic Kidney Diseases.

Is NCT06578533 still recruiting?

NCT06578533 is currently recruiting now. Last updated 29 August 2024.

Last reviewed 2024-08-29 · How we verify

NCT06578533: KEEP-ON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Keeping RAASi Treatment With Optimal Potassium Control

Recruiting now Phase 3 Last updated 29 August 2024

What this trial tests

Phase 3 trial testing Sodium Zirconium Cyclosilicate in Chronic Kidney Diseases in 78 participants. Currently enrolling.

Timeline

30 September 2022

Primary endpoint
30 July 2025

30 July 2026

Quick facts

Lead sponsor	Fundación para la Investigación del Hospital Clínico de Valencia
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	30 September 2022
Primary completion	30 July 2025
Estimated completion	30 July 2026
Sites	5 locations across Spain

Drugs / interventions tested

Sodium Zirconium Cyclosilicate — full drug profile →

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Who can join

18 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

What to do with key cardiovascular drugs when kidney function worsens?
Bergen K, Spaak J. · · 2026 · PMID 41531854 · DOI 10.1093/ckj/sfaf354

Verify or expand the search:

Other trials of Sodium Zirconium Cyclosilicate

Trials testing the same drug.

NCT06578078 — A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · recruiting
NCT04983979 — The ORTIZ Study: Optimising RASi Therapy With SZC · Phase 2 · terminated
NCT04788641 — Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in He · Phase 1 · completed
NCT04217590 — Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects · Phase 3 · completed
NCT03532009 — Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure · Phase 2 · terminated

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other Fundación para la Investigación del Hospital Clínico de Valencia trials

Trials by the same sponsor.

NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
NCT07291999 — Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry · active not recruiting
NCT06655532 — Effects of an Exercise Program in Women Over 60 yr. With HFpEF and Sarcopenia on Functional Capacity and Quality of Life · NA · not yet recruiting
NCT06578078 — A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · recruiting
NCT06578520 — Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06578533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación para la Investigación del Hospital Clínico de Valencia
Last refreshed: 29 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06578533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing